• 1
    Centers for Disease Control and Prevention. Hepatitis Surveillance Report No. 60. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2005.
  • 2
    Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR07): 123.
  • 3
    Kusov Y, Kanda T, Palmenberg A, Sgro JY, Gauss-Muller V. Silencing of hepatitis A virus infection by small interfering RNAs. J Virol 2006; 80: 55995610.
  • 4
    Strom SC, Bruzzone P, Cai H, Ellis E, Lehmann T, Mitamura K, et al. Hepatocyte transplantation: clinical experience and potential for future use. Cell Transplant 2006; 15(Suppl 1): S105S110.
  • 5
    Eisenbach C, Longerich T, Fickenscher H, Schalasta G, Stremmel W, Encke J. Recurrence of clinically significant hepatitis A following liver transplantation for fulminant hepatitis A. J Clin Virol 2006; 35: 109112.
  • 6
    Sjogren M. Immunization and the decline of viral hepatitis as a cause of acute liver failure. HEPATOLOGY 2003; 38: 554556.
  • 7
    Taylor R, Davern T, Munoz S, Han S-H, McGuire B, Larson AM, et al. Fulminant hepatitis A virus infection in the United States: incidence, prognosis, and outcomes. HEPATOLOGY 2006; 44: 15891597.
  • 8
    Squires RH Jr, Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006; 148: 652658.
  • 9
    Ellis AJ, Saleh M, Smith H, Portmann B, Gimson A, Williams R. Late-onset hepatic failure: clinical features, serology and outcome following transplantation. J Hepatol 1995; 23: 363372.
  • 10
    Polson J, Lee WM. AASLD position paper: the management of acute liver failure. HEPATOLOGY 2005; 41: 11791197.
  • 11
    Lee WS, McKiernan P, Kelly DA. Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United Kingdom. J Pediatr Gastroenterol Nutr 2005; 40: 575581.
  • 12
    Saab S, Lee C, Shpaner A, Ibrahim AB. Seroepidemiology of hepatitis A in patients with chronic liver disease. J Viral Hepat 2005; 12: 101105.
  • 13
    Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286290.
  • 14
    Sagnelli E, Coppola N, Pisaturo M, Pisapia R, Onofrio M, Sagnelli C, et al. Clinical and virologic improvement of hepatitis B virus-related or hepatitis C virus-related chronic hepatitis with concomitant hepatitis A virus infection, Clin Infect Dis 2006; 42: 15361543.
  • 15
    Jacobs RJ, Koff RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am J Gastroenterol 2002; 97: 427434.
  • 16
    Arguedas MR, Heudebert GR, Fallon MB, Stinnett AA. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Am J Gastroenterol 2002; 97: 721728.
    Direct Link:
  • 17
    Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children, adolescents and adults. HEPATOLOGY 2003; 37: 4451.